Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Budesonide Market Expected To Grow In Terms Of Size?

The budesonide market has witnessed significant expansion in the past few years. From $9.72 billion in 2024, it is projected to reach $10.26 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.6%. Factors that contributed to this increase throughout the historic period encompass the escalating instances of respiratory ailments, heightened awareness regarding inhaled corticosteroids, the launch of budesonide-based combined therapies, enhanced access to healthcare and improvement in healthcare infrastructures, as well as the approval of budesonide for off-label use to treat inflammatory bowel diseases.

In the upcoming years, the budesonide market is projected to experience robust growth, expanding to “$12.95 billion in 2029 with a compound annual growth rate (CAGR) of 6.0%. The anticipated increase in the forecast period is due to rising demand for effective therapies, the introduction of innovative drug delivery systems, the growing usage of budesonide, an increase in the elderly population susceptible to asthma, and the proliferation of generic budesonide products. Key trends expected during the forecast period include the implementation of biologics and biosimilars, advancements in drug delivery methods, regulatory approvals for new formulations, breakthroughs in drug delivery system development, and technological progression.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Budesonide Market?

The growth of the budesonide market is expected to be accelerated by a surge in the incidence of respiratory conditions. Such conditions include diseases impacting the organs and tissues in air-breathing animals that are involved in gas exchange. The rising prevalence of these conditions can be attributed to increased air pollution, including exposure to particulates and allergens, which notably influence the occurrence of asthma and chronic obstructive lung disease. Budesonide is employed as treatment for these conditions, including asthma and chronic obstructive pulmonary disease (COPD), as it reduces inflammation, improves airflow, and prevents symptoms like wheezing and breathlessness. For instance, the National Center for Health Statistics (NCHS), a US-based health statistics agency, reported in May 2024 that the current asthma prevalence among adults over 18 in the United States climbed from 8.4% in 2021 to 8.7% in 2022. Moreover, the number of asthma episodes that occurred among adults of the same age group in the past 12 months increased from 3.3% in 2021 to 3.7% in 2022. Consequently, the rising incidence of respiratory conditions is expected to prompt growth within the budesonide market.

Which Segment Accounts For The Largest Share In The Budesonide Market?

The budesonide market covered in this report is segmented –

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:

1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)

2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers

3) By Injectable Suspension: Pre-filled Syringes, Vials

4) By Tablets And Capsules: Oral Tablets, Oral Capsules

Which Long-Term Trends Will Play A Crucial Role In The Budesonide Market?

Leading firms in the budesonide market are prioritizing innovations in respiratory care, like oral treatments, to not only enhance patient comfort but also expand therapy choices for dealing with asthma and other respiratory diseases. Oral budesonide, which is ingested, is mainly used for inflammatory conditions. For example, in February 2024, Japan’s Takeda Pharmaceuticals revealed that EOHILIA, an oral suspension of budesonide, has been approved as the first and sole oral drug for eosinophilic esophagitis (EoE) in patients aged 11 and older by the Food and Drug Administration (FDA), a federal agency in the US. Moreover, based on efficacy and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week studies in people aged 11 to 56 with EoE, the FDA also greenlighted EOHILIA 2 mg to be used twice daily.

Which Organizations Are At The Forefront Of The Budesonide Market?

Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

Which Region Is Forecasted To Lead The Budesonide Market In The Coming Years?

North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model